Galectin Sciences

Galectin Sciences is a private biotechnology company dedicated to developing next-generation small molecule inhibitors of galectin proteins, with a primary focus on Galectin-3. The company was founded by Dr. Peter Traber, a leading expert in galectin biology and former CEO of Galectin Therapeutics, to address the limitations of large-molecule carbohydrate-based inhibitors. Their lead programs target fibrotic conditions such as metabolic dysfunction-associated steatohepatitis (MASH) and various oncological indications. By utilizing a small molecule approach, the company aims to provide orally bioavailable treatments that can effectively modulate the carbohydrate recognition domain of galectins. Galectin Sciences operates as a lean research and development organization focused on high-potency medicinal chemistry and selective targeting.